Spero Therapeutics Inc (SPRO)
1.24
-0.07
(-5.34%)
USD |
NASDAQ |
Nov 14, 12:48
Spero Therapeutics Revenue (Quarterly): 6.017M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 6.017M |
March 31, 2024 | 4.204M |
December 31, 2023 | 71.82M |
September 30, 2023 | 23.38M |
June 30, 2023 | 0.788M |
March 31, 2023 | 0.74M |
December 31, 2022 | 46.35M |
September 30, 2022 | 1.082M |
June 30, 2022 | 0.896M |
March 31, 2022 | 0.247M |
December 31, 2021 | 0.256M |
September 30, 2021 | 0.708M |
June 30, 2021 | 2.106M |
Date | Value |
---|---|
March 31, 2021 | |
December 31, 2020 | -7.165M |
September 30, 2020 | 3.995M |
June 30, 2020 | 1.727M |
March 31, 2020 | 1.701M |
December 31, 2019 | -9.775M |
September 30, 2019 | 4.643M |
June 30, 2019 | 2.156M |
March 31, 2019 | 3.807M |
December 31, 2018 | |
September 30, 2018 | |
June 30, 2018 | 0.463M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-9.775M
Minimum
Dec 2019
71.82M
Maximum
Dec 2023
8.283M
Average
1.392M
Median
Revenue (Quarterly) Benchmarks
Arbutus Biopharma Corp | 1.339M |
Equillium Inc | 13.85M |
NovaBay Pharmaceuticals Inc | 2.40M |
Palatin Technologies Inc | 0.35M |
iBio Inc | 0.175M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -17.86M |
Total Expenses (Quarterly) | 25.08M |
EPS Diluted (Quarterly) | -0.33 |
Enterprise Value | 7.277M |
Profit Margin (Quarterly) | -296.9% |
Earnings Yield | 27.42% |
Operating Earnings Yield | 31.40% |
Normalized Earnings Yield | 33.83 |